Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage IIIC‑IV ovarian cancer and poor general condition

  • Authors:
    • Suzuyo Takahashi
    • Yuji Takei
    • Kohei Tamura
    • Akiyo Taneichi
    • Yoshifumi Takahashi
    • Takahiro Yoshiba
    • Takahiro Koyanagi
    • Risa Narumi
    • Yasushi Saga
    • Hiroyuki Fujiwara
  • View Affiliations

  • Published online on: November 21, 2021     https://doi.org/10.3892/mco.2021.2449
  • Article Number: 14
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has remained elusive whether standard chemotherapy regimens are safe for patients with ovarian cancer and poor general condition. The purpose of the present study was to assess the response to and toxicity of weekly paclitaxel and carboplatin (W‑PC) in patients with ovarian cancer and poor general condition. The subjects were patients with ovarian cancer who received W‑PC at Jichi Medical University Hospital (Shimotsuke, Japan) between January 2008 and December 2016. Patients who were ≥80 years old and/or had a performance status ≥3 and/or severe complications/underlying diseases were selected. Patients received paclitaxel (60 mg/m2) and carboplatin (area under the curve 2 mg/ml/min) on days 1, 8, and 15 of a 28‑day cycle. Their medical records were retrospectively reviewed. A total of 31 patients were included in the study. Grade 3/4 neutropenia, anemia and thrombocytopenia developed in 18 (58%), 5 (16%) and 1 (3%) patients, respectively. Furthermore, three (10%) patients had a complete response (CR), 12 (39%) had a partial response (PR), 5 (16%) had stable disease and 11 (35%) had progressive disease. The overall response rate was 48% (15/31) and the disease control rate was 65% (20/31). The 5‑year progression‑free survival was 15% and the 5‑year overall survival was 15%. A total of 9 patients survived for >40 months, one of whom survived without recurrence for 122 months. Performance status <3, a tumor response of CR or PR and >5 chemotherapy cycles were indicators of favorable prognosis. Only >5 chemotherapy cycles (vs. ≤5; P=0.002) was an independent good prognostic factor according to multivariate analysis. In conclusion, W‑PC was tolerable and slightly effective in patients with ovarian cancer and poor general condition. W‑PC may be one option for patients who are unable to receive standard chemotherapy regimens.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 16 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takahashi S, Takei Y, Tamura K, Taneichi A, Takahashi Y, Yoshiba T, Koyanagi T, Narumi R, Saga Y, Fujiwara H, Fujiwara H, et al: Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage IIIC‑IV ovarian cancer and poor general condition. Mol Clin Oncol 16: 14, 2022
APA
Takahashi, S., Takei, Y., Tamura, K., Taneichi, A., Takahashi, Y., Yoshiba, T. ... Fujiwara, H. (2022). Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage IIIC‑IV ovarian cancer and poor general condition. Molecular and Clinical Oncology, 16, 14. https://doi.org/10.3892/mco.2021.2449
MLA
Takahashi, S., Takei, Y., Tamura, K., Taneichi, A., Takahashi, Y., Yoshiba, T., Koyanagi, T., Narumi, R., Saga, Y., Fujiwara, H."Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage IIIC‑IV ovarian cancer and poor general condition". Molecular and Clinical Oncology 16.1 (2022): 14.
Chicago
Takahashi, S., Takei, Y., Tamura, K., Taneichi, A., Takahashi, Y., Yoshiba, T., Koyanagi, T., Narumi, R., Saga, Y., Fujiwara, H."Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage IIIC‑IV ovarian cancer and poor general condition". Molecular and Clinical Oncology 16, no. 1 (2022): 14. https://doi.org/10.3892/mco.2021.2449